Ratios

		vs industry	vs history
P/B	16.30	IGXT's P/B is ranked lower than 63% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 3.80 vs. IGXT: 16.30 )	IGXT' s 10-Year P/B Range Min: 4.38   Max: 117 Current: 16.3 4.38 117
P/S	25.25	IGXT's P/S is ranked lower than 85% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 6.90 vs. IGXT: 25.25 )	IGXT' s 10-Year P/S Range Min: 6.25   Max: 58.5 Current: 25.25 6.25 58.5
EV-to-EBIT	8.8	IGXT's EV-to-EBIT is ranked higher than 78% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 14.61 vs. IGXT: 8.8 )	IGXT' s 10-Year EV-to-EBIT Range Min: 0   Max: 0 Current: 8.8

Valuation & Return

		vs industry	vs history
Price/Net Current Asset Value	32	IGXT's Price/Net Current Asset Value is ranked higher than 81% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 32.60 vs. IGXT: 32 )	IGXT' s 10-Year Price/Net Current Asset Value Range Min: 15.5   Max: 32.5 Current: 32 15.5 32.5
Price/Tangible Book	16	IGXT's Price/Tangible Book is ranked higher than 88% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 4.70 vs. IGXT: 16 )	IGXT' s 10-Year Price/Tangible Book Range Min: 6.9   Max: 80 Current: 16 6.9 80
Price/Median PS Value	2	IGXT's Price/Median PS Value is ranked higher than 89% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 0.90 vs. IGXT: 2 )	IGXT' s 10-Year Price/Median PS Value Range Min: 0.6   Max: 1.4 Current: 2 0.6 1.4
Forward Rate of Return (Yacktman)	-35.46	IGXT's Forward Rate of Return (Yacktman) is ranked higher than 69% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: -4.65 vs. IGXT: -35.46 )	IGXT' s 10-Year Forward Rate of Return (Yacktman) Range Min: 33.1   Max: 97.3 Current: -35.46 33.1 97.3

Business Description

IntelGenx Technologies Corp. (formerly known as Big Flash Corp) was incorporated in the State of Delaware. The Company is focused on the development of novel oral immediate release and controlled-release products for the branded and generic pharmaceutical market. It provides product development services for the pharmaceutical industry, including the branded and generic pharmaceutical markets. The Company develops pharmaceutical products based upon its proprietary drug delivery technologies and licenses the commercial rights to companies in the pharmaceutical industry once the viability of a product has been demonstrated to license the commercial rights to partners in the pharmaceutical industry. IntelGenx is currently continuing to develop the existing products in its pipeline and might on other potential products as opportunities arise. Its product development efforts are based upon three delivery platform technologies: a Multilayer Tablet technology; an Oral Film technology, and a Mucoadhesive Tablet technology. The Multilayer Tablet ('VersaTab') platform technology represents a new generation of controlled release layered tablets designed to modulate the release of active compounds. The oral film technology is made up of a thin (25-35 micron) polymeric film comprised of USP components that are approved by the FDA for use in food, pharmaceutical, and cosmetic products. The Mucoadhesive Tablet ('AdVersa') is a drug delivery system capable of adhering to the oral mucosa and releasing the drug onto the site of application at a controlled rate. The Company plans to develop additional products for the nutritional supplement market based upon its proprietary drug delivery technologies. The pharmaceutical industry is highly competitive and is subject to the rapid emergence of new technologies, governmental regulations, healthcare legislation, availability of financing, patent litigation and other factors. Its competitors are Biovail Corporation, Labopharm Inc., and Flamel Technologies S.A. The Company is subject to rigorous regulation by the FDA.
Company Website

Industry:	Biotechnology
Compare:
Traded in other countries:	IGX.Canada

Personalized Checklist